Global Acute Agitation and Aggression Treatment Market
Global Acute Agitation and Aggression Treatment Market

Acute Agitation and Aggression Treatment Comprehensive Study by Therapy (Chemotherapy, Cognitive Behavioural Therapy (CBT), Others), Route of Administration (Oral, Sublingual, Intramuscular, Others), End Use (Hospitals & Clinics, Psychiatric Research Institutes, Psychiatric Care Centers, Others), Disorder Type (Schizophrenia, Comorbid Heart Disease, Dementia, Alzheimer, Bipolar, Others), Drug Class (Antipsychotics, • Conventional, • Atypical, Benzodiazepines, Butyrophenones)

Acute Agitation and Aggression Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 250 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Acute Agitation and Aggression Treatment?
Acute agitation & aggressive treatments are defined as a collection of intensive-care-unit stay, resuscitation, and antibiotics to treat behavioural dyscontrol. Agitation is an excessive verbal and physical behaviour which can be intensify to aggression. This treatment is mainly arrived in different of medical and psychiatric conditions. It is particularly results in behavioural dyscontrol. Changing lifestyle and strong attention towards socialism and eager towards gaining social attentions, mental burden leads behavioural changes. Thus, to treat mental illness and manage mental health and to avoid acute agitation, different treatment are recommended. This treatments use of medication to calm agitated patients and lowers it’s ascertain dangerous behaviour. Certain therapy are used to treat and reduce aggressive behaviour in an adult. For instance, cognitive behavioural therapy (CBT) is used to treat acute agitation. Increasing awareness regarding mental sickness and availability of treatment is driving the demand for the market. Further, rising prevalence of psychiatric disorders demands for the treatments. However, less alertness regarding mental illness in certain emerging regions providing challenge to the market.

The market study is broken down and major geographies with country level break-up.

Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Hoffmann-La Roche Ltd. (United States), Astra Zeneca (United Kingdom), AbbVie Inc. (United States), Celgene (United States), Eli Lilly & Co (United States), Cadila Healthcare Limited (India), Dr. Reddy’s Laboratories Ltd. (India) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Acute Agitation and Aggression Treatment market by Type, Application and Region.

On the basis of geography, the market of Acute Agitation and Aggression Treatment has been segmented into . If we see Market by Therapy, the sub-segment i.e. Chemotherapy will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals & Clinics will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disorder Type , the sub-segment i.e. Schizophrenia will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Antipsychotics will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Leaders and their expansionary development strategies
In February 2018, BullFrog AI, Inc, has established partnership with Lieber Institute for Brain Development. This is medical research institute working for mental disorders and its treatment. BullFrog AI, Inc is industry leader in AI and clinical data analytics services. With this partnership, company is able use its AI platform to analyse anti-psychotic drug responses. In addition, BullFrog AI is utilize their platform to analyse large multi-factorial clinical data of patients who received antipsychotic medication.
In June 2020, Sumitomo Dainippon Pharma has launched Atypical Antipsychotic Agent, LATUDA Tablets in Japan. It is an atypical antipsychotic agent for schizophrenia and bipolar depression. It has high tolerability and it is a first medication for the treatment of both diseases. With this new launch, company is able to provide generic version which have huge affordability for patients.
Regulation (EC) No 726/2004- Regarding the use of conventional antipsychotics to treat dementia. It is approved by (CHMP) The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines.

Market Trend
  • Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Psychiatric Disorders

Market Drivers
  • Growing Awareness Regarding Mental Illness
  • Increasing Incidences of Psychiatric Disorders across the Globe
  • Rising Attention towards Maintaining Mental Health with Proper Treatment
  • Augmenting Government Spending’s On Psychiatric Research Institutes & Care Centers

Opportunities
  • Rising Approvals for Antipsychotics Drugs to Treat Bipolar Disorders, Psychiatric Disorders and Mental Illness Has Created Growth Opportunities for Market
  • Surge in Prescriptions of Anti-Psychotics
  • Introduction of AI in the Treatments & Clinical Data Analysis

Restraints
  • Lack of Education Regarding Acute Agitation and Aggression & Mental Illness
  • Side Effects Associated With Antipsychotics Drugs Expected To Hamper Its Demand
  • Straighten Regulatory Norms

Challenges
  • Huge Requirement of Investments for Drug Developments


Key Target Audience
Acute Agitation and Aggression Treatment Manufacturers, Antipsychotics Manufacturers/Suppliers/Distributor, Raw Material Suppliers, Psychiatric Research Centers, New Entrants/Investors, Strategic Business Planners, Governments and Healthcare & Pharmaceutical Industry

About Approach
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Therapy
  • Chemotherapy
  • Cognitive Behavioural Therapy (CBT)
  • Others

By Route of Administration
  • Oral
  • Sublingual
  • Intramuscular
  • Others

By End Use
  • Hospitals & Clinics
  • Psychiatric Research Institutes
  • Psychiatric Care Centers
  • Others

By Disorder Type
  • Schizophrenia
  • Comorbid Heart Disease
  • Dementia
  • Alzheimer
  • Bipolar
  • Others

By Drug Class
  • Antipsychotics
  • • Conventional
  • • Atypical
  • Benzodiazepines
  • Butyrophenones

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Dynamics
      • 3.1. Introduction
      • 3.2. Market Drivers
        • 3.2.1. Growing Awareness Regarding Mental Illness
        • 3.2.2. Increasing Incidences of Psychiatric Disorders across the Globe
        • 3.2.3. Rising Attention towards Maintaining Mental Health with Proper Treatment
        • 3.2.4. Augmenting Government Spending’s On Psychiatric Research Institutes & Care Centers
      • 3.3. Market Challenges
        • 3.3.1. Huge Requirement of Investments for Drug Developments
      • 3.4. Market Trends
        • 3.4.1. Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Psychiatric Disorders
    • 4. Market Factor Analysis
      • 4.1. Porters Five Forces
      • 4.2. Supply/Value Chain
      • 4.3. PESTEL analysis
      • 4.4. Market Entropy
      • 4.5. Patent/Trademark Analysis
    • 5. Global Acute Agitation and Aggression Treatment, by Therapy, Route of Administration, End Use, Disorder Type and Drug Class (value) (2015-2020)
      • 5.1. Introduction
      • 5.2. Global Acute Agitation and Aggression Treatment (Value)
        • 5.2.1. Global Acute Agitation and Aggression Treatment by: Therapy (Value)
          • 5.2.1.1. Chemotherapy
          • 5.2.1.2. Cognitive Behavioural Therapy (CBT)
          • 5.2.1.3. Others
        • 5.2.2. Global Acute Agitation and Aggression Treatment by: Route of Administration (Value)
          • 5.2.2.1. Oral
          • 5.2.2.2. Sublingual
          • 5.2.2.3. Intramuscular
          • 5.2.2.4. Others
        • 5.2.3. Global Acute Agitation and Aggression Treatment by: End Use (Value)
          • 5.2.3.1. Hospitals & Clinics
          • 5.2.3.2. Psychiatric Research Institutes
          • 5.2.3.3. Psychiatric Care Centers
          • 5.2.3.4. Others
        • 5.2.4. Global Acute Agitation and Aggression Treatment by: Drug Class (Value)
          • 5.2.4.1. Antipsychotics
          • 5.2.4.2. • Conventional
          • 5.2.4.3. • Atypical
          • 5.2.4.4. Benzodiazepines
          • 5.2.4.5. Butyrophenones
    • 6. Acute Agitation and Aggression Treatment: Manufacturers/Players Analysis
      • 6.1. Competitive Landscape
        • 6.1.1. Market Share Analysis
          • 6.1.1.1. Top 3
          • 6.1.1.2. Top 5
      • 6.2. Peer Group Analysis (2020)
      • 6.3. BCG Matrix
      • 6.4. Company Profile
        • 6.4.1. Bristol-Myers Squibb (United States)
          • 6.4.1.1. Business Overview
          • 6.4.1.2. Products/Services Offerings
          • 6.4.1.3. Financial Analysis
          • 6.4.1.4. SWOT Analysis
        • 6.4.2. Johnson & Johnson (United States)
          • 6.4.2.1. Business Overview
          • 6.4.2.2. Products/Services Offerings
          • 6.4.2.3. Financial Analysis
          • 6.4.2.4. SWOT Analysis
        • 6.4.3. Pfizer Inc. (United States)
          • 6.4.3.1. Business Overview
          • 6.4.3.2. Products/Services Offerings
          • 6.4.3.3. Financial Analysis
          • 6.4.3.4. SWOT Analysis
        • 6.4.4. Hoffmann-La Roche Ltd. (United States)
          • 6.4.4.1. Business Overview
          • 6.4.4.2. Products/Services Offerings
          • 6.4.4.3. Financial Analysis
          • 6.4.4.4. SWOT Analysis
        • 6.4.5. Astra Zeneca (United Kingdom)
          • 6.4.5.1. Business Overview
          • 6.4.5.2. Products/Services Offerings
          • 6.4.5.3. Financial Analysis
          • 6.4.5.4. SWOT Analysis
        • 6.4.6. AbbVie Inc. (United States)
          • 6.4.6.1. Business Overview
          • 6.4.6.2. Products/Services Offerings
          • 6.4.6.3. Financial Analysis
          • 6.4.6.4. SWOT Analysis
        • 6.4.7. Celgene (United States)
          • 6.4.7.1. Business Overview
          • 6.4.7.2. Products/Services Offerings
          • 6.4.7.3. Financial Analysis
          • 6.4.7.4. SWOT Analysis
        • 6.4.8. Eli Lilly & Co (United States)
          • 6.4.8.1. Business Overview
          • 6.4.8.2. Products/Services Offerings
          • 6.4.8.3. Financial Analysis
          • 6.4.8.4. SWOT Analysis
        • 6.4.9. Cadila Healthcare Limited (India)
          • 6.4.9.1. Business Overview
          • 6.4.9.2. Products/Services Offerings
          • 6.4.9.3. Financial Analysis
          • 6.4.9.4. SWOT Analysis
        • 6.4.10. Dr. Reddy’s Laboratories Ltd. (India)
          • 6.4.10.1. Business Overview
          • 6.4.10.2. Products/Services Offerings
          • 6.4.10.3. Financial Analysis
          • 6.4.10.4. SWOT Analysis
        • 6.4.11. GlaxoSmithKline plc (United Kingdom)
          • 6.4.11.1. Business Overview
          • 6.4.11.2. Products/Services Offerings
          • 6.4.11.3. Financial Analysis
          • 6.4.11.4. SWOT Analysis
    • 7. Global Acute Agitation and Aggression Treatment Sale, by Therapy, Route of Administration, End Use, Disorder Type and Drug Class (value) (2021-2026)
      • 7.1. Introduction
      • 7.2. Global Acute Agitation and Aggression Treatment (Value)
        • 7.2.1. Global Acute Agitation and Aggression Treatment by: Therapy (Value)
          • 7.2.1.1. Chemotherapy
          • 7.2.1.2. Cognitive Behavioural Therapy (CBT)
          • 7.2.1.3. Others
        • 7.2.2. Global Acute Agitation and Aggression Treatment by: Route of Administration (Value)
          • 7.2.2.1. Oral
          • 7.2.2.2. Sublingual
          • 7.2.2.3. Intramuscular
          • 7.2.2.4. Others
        • 7.2.3. Global Acute Agitation and Aggression Treatment by: End Use (Value)
          • 7.2.3.1. Hospitals & Clinics
          • 7.2.3.2. Psychiatric Research Institutes
          • 7.2.3.3. Psychiatric Care Centers
          • 7.2.3.4. Others
        • 7.2.4. Global Acute Agitation and Aggression Treatment by: Drug Class (Value)
          • 7.2.4.1. Antipsychotics
          • 7.2.4.2. • Conventional
          • 7.2.4.3. • Atypical
          • 7.2.4.4. Benzodiazepines
          • 7.2.4.5. Butyrophenones
    • 8. Appendix
      • 8.1. Acronyms
    • 9. Methodology and Data Source
      • 9.1. Methodology/Research Approach
        • 9.1.1. Research Programs/Design
        • 9.1.2. Market Size Estimation
        • 9.1.3. Market Breakdown and Data Triangulation
      • 9.2. Data Source
        • 9.2.1. Secondary Sources
        • 9.2.2. Primary Sources
      • 9.3. Disclaimer
    List of Tables
    • Table 1. Acute Agitation and Aggression Treatment: by Therapy(USD Million)
    • Table 2. Acute Agitation and Aggression Treatment: by Route of Administration(USD Million)
    • Table 3. Acute Agitation and Aggression Treatment: by End Use(USD Million)
    • Table 4. Acute Agitation and Aggression Treatment: by Drug Class(USD Million)
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Acute Agitation and Aggression Treatment: by Therapy(USD Million)
    • Table 17. Acute Agitation and Aggression Treatment: by Route of Administration(USD Million)
    • Table 18. Acute Agitation and Aggression Treatment: by End Use(USD Million)
    • Table 19. Acute Agitation and Aggression Treatment: by Drug Class(USD Million)
    • Table 20. Research Programs/Design for This Report
    • Table 21. Key Data Information from Secondary Sources
    • Table 22. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. Global Acute Agitation and Aggression Treatment: by Therapy USD Million (2015-2020)
    • Figure 5. Global Acute Agitation and Aggression Treatment: by Route of Administration USD Million (2015-2020)
    • Figure 6. Global Acute Agitation and Aggression Treatment: by End Use USD Million (2015-2020)
    • Figure 7. Global Acute Agitation and Aggression Treatment: by Drug Class USD Million (2015-2020)
    • Figure 8. Global Acute Agitation and Aggression Treatment share by Players 2020 (%)
    • Figure 9. Global Acute Agitation and Aggression Treatment share by Players (Top 3) 2020(%)
    • Figure 10. Global Acute Agitation and Aggression Treatment share by Players (Top 5) 2020(%)
    • Figure 11. BCG Matrix for key Companies
    • Figure 12. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
    • Figure 13. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
    • Figure 14. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
    • Figure 15. Johnson & Johnson (United States) Revenue: by Geography 2020
    • Figure 16. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 17. Pfizer Inc. (United States) Revenue: by Geography 2020
    • Figure 18. Hoffmann-La Roche Ltd. (United States) Revenue, Net Income and Gross profit
    • Figure 19. Hoffmann-La Roche Ltd. (United States) Revenue: by Geography 2020
    • Figure 20. Astra Zeneca (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 21. Astra Zeneca (United Kingdom) Revenue: by Geography 2020
    • Figure 22. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
    • Figure 23. AbbVie Inc. (United States) Revenue: by Geography 2020
    • Figure 24. Celgene (United States) Revenue, Net Income and Gross profit
    • Figure 25. Celgene (United States) Revenue: by Geography 2020
    • Figure 26. Eli Lilly & Co (United States) Revenue, Net Income and Gross profit
    • Figure 27. Eli Lilly & Co (United States) Revenue: by Geography 2020
    • Figure 28. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
    • Figure 29. Cadila Healthcare Limited (India) Revenue: by Geography 2020
    • Figure 30. Dr. Reddy’s Laboratories Ltd. (India) Revenue, Net Income and Gross profit
    • Figure 31. Dr. Reddy’s Laboratories Ltd. (India) Revenue: by Geography 2020
    • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
    • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
    • Figure 34. Global Acute Agitation and Aggression Treatment: by Therapy USD Million (2021-2026)
    • Figure 35. Global Acute Agitation and Aggression Treatment: by Route of Administration USD Million (2021-2026)
    • Figure 36. Global Acute Agitation and Aggression Treatment: by End Use USD Million (2021-2026)
    • Figure 37. Global Acute Agitation and Aggression Treatment: by Drug Class USD Million (2021-2026)
    Some of the key companies/manufacturers profiled in the report
    • Bristol-Myers Squibb (United States)
    • Johnson & Johnson (United States)
    • Pfizer Inc. (United States)
    • Hoffmann-La Roche Ltd. (United States)
    • Astra Zeneca (United Kingdom)
    • AbbVie Inc. (United States)
    • Celgene (United States)
    • Eli Lilly & Co (United States)
    • Cadila Healthcare Limited (India)
    • Dr. Reddy’s Laboratories Ltd. (India)
    • GlaxoSmithKline plc (United Kingdom)
    Select License Type
    Sample Report Enquiry Before Buy Request Discount

    Speak with Analyst

    Want to find out more about this report?

    Get Free Consultation